KLOW

Overview

What it is, in plain language

KLOW is the second-generation evolution of GLOW. It carries the same three regenerative peptides — BPC-157, GHK-Cu, TB-500 — and adds KPV, a tripeptide fragment of alpha-MSH with potent anti-inflammatory activity.

Where GLOW is positioned for clean regenerative and aesthetic work, KLOW is positioned for contexts where active inflammation needs to be controlled alongside the rebuild — post-procedure recovery, gut–skin axis protocols, autoimmune-adjacent skin research, and any setting where the repair signal is being applied against an inflammatory backdrop.

Four peptides, four arms of repair — signal, mobilisation, structure, and inflammation — in one daily administration.

Mechanism

How it works

BPC-157 drives the repair signal and angiogenesis. TB-500 mobilises cells to the repair site. GHK-Cu rebuilds structural proteins (collagen, elastin, glycosaminoglycans). KPV suppresses pro-inflammatory cytokines (TNF-α, NF-κB pathway), with documented gut-targeting activity. The four peptides operate on distinct mechanisms and the blend delivers all four arms of repair in one administration.

Research findings

What the literature shows

Each component is independently supported by preclinical literature. KPV specifically has documented anti-inflammatory effects in colitis and dermatitis research models.

Combination protocols are reported anecdotally as broader-spectrum than GLOW, with the inflammation arm being the principal differentiator. The KPV addition is what carries KLOW into post-procedure and gut–skin contexts that GLOW alone is not optimised for.

Cycle & Handling

Protocol reference

Common research-grade reference figures. Not medical advice — every protocol must be reviewed against the latest published literature and your study design.

Cycle guidance

Standard 4–6 weeks on, 4 weeks off. Extended 8-week option for post-procedure or active inflammatory protocols. Annual ceiling: 2–3 cycles. Do not layer additional BPC-157, GHK-Cu, TB-500, or KPV on top of an active KLOW cycle. MOTS-c can run in parallel without overlap.

Reconstitution

2 mL BAC → 40 mg/mL total. Draw 0.2 mL ≈ 8 mg total per dose.

Storage

Lyophilised vial: room temperature short-term, refrigerator long-term. Reconstituted: refrigerate; use within 28 days when reconstituted with bacteriostatic water. Protect from light.

FAQ